Drug Type Monoclonal antibody |
Synonyms TQB 2618, TQB2618 |
Target |
Mechanism TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | CN | 26 May 2023 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | CN | 23 May 2023 | |
Squamous cell carcinoma, metastatic | Phase 2 | CN | 23 May 2023 | |
Nasopharyngeal Carcinoma | Phase 2 | CN | 27 Oct 2022 | |
Recurrent Lymphoma | Phase 2 | CN | 09 Jun 2022 | |
Refractory Lymphoma | Phase 2 | CN | 09 Jun 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 28 Apr 2022 | |
Squamous cell carcinoma of head and neck metastatic | Phase 1 | CN | 14 Mar 2024 | |
Colorectal Cancer | Phase 1 | CN | 22 Dec 2023 | |
Advanced Hepatocellular Carcinoma | Phase 1 | CN | 15 Aug 2023 |
WCLC2024 Manual | Phase 1 | 93 | (jsunglbcfr) = kvigtydmtb bhnkkvpzeq (wpnzhplplc ) View more | Positive | 10 Sep 2024 | ||
(jsunglbcfr) = ztcvdquhwh bhnkkvpzeq (wpnzhplplc ) View more | |||||||
NCT05400876 (EHA2024) Manual | Phase 1 | 21 | rcklrjruqk(tglgemywmx) = 17 (81%) patients experienced treatment-related adverse events (TRAEs), 5 (23.8%) of whom experienced grade 3 or above TRAEs. The most frequent TRAEs (≥15%) were platelet count decreased (23.8%), anemia (23.8%), alanine aminotransferase increased (19%) and Aspartate aminotransferase increased (19%). The most common grade 3 or above TRAEs were anemia (9.5%) and white blood count decreased (9.5%). jlssfzorcs (zjxngfdiqy ) View more | Positive | 14 May 2024 |